Related Experiment Videos
Heparin-induced thrombosis treated with ancrod
1Department of Surgery, Camp Hill Hospital, Halifax, NS.
Summary
Heparin therapy can cause immune reactions like thrombocytopenia and thrombosis. A case study shows successful treatment with thrombectomy, warfarin, and ancrod, a fibrinolytic agent.
Area of Science:
- Hematology
- Immunology
- Pharmacology
Background:
- Heparin is a common anticoagulant for thromboembolic disease.
- Heparin can trigger immune responses, including heparin-induced thrombocytopenia (HIT).
- HIT can lead to serious complications like thrombosis.
Observation:
- A 70-year-old woman developed heparin-induced thrombocytopenia with thrombosis.
- The patient's condition arose despite ongoing heparin therapy.
Findings:
- Successful treatment involved thrombectomy and anticoagulation with warfarin and ancrod.
- Ancrod, a natural fibrinolytic agent, was administered.
- The case highlights the potential for late-onset HIT.
Implications:
- Close monitoring for hematologic disorders is crucial for patients on heparin.
- Ancrod presents a viable therapeutic option for managing heparin-induced thrombosis.
- Understanding HIT mechanisms is vital for patient safety in anticoagulant therapy.